HLA-DRB1 typing in rheumatoid arthritis

Predicting response to specific treatments

James Robert O'Dell, Barbara S. Nepom, Claire Haire, Vivian H. Gersuk, Lakshmi Gaur, Gerald Francis Moore, Walter Drymalski, William Palmer, P. James Eckhoff, Lynell Warren Klassen, Steven Wees, Geoffrey Milton Thiele, Gerald T. Nepom

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.

Original languageEnglish (US)
Pages (from-to)209-213
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume57
Issue number4
DOIs
StatePublished - Jan 1 1998

Fingerprint

HLA-DRB1 Chains
Histocompatibility Testing
Epitopes
Rheumatoid Arthritis
Methotrexate
Hydroxychloroquine
Sulfasalazine
Therapeutics
Alleles
Antirheumatic Agents
Therapeutic Uses
Genes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

HLA-DRB1 typing in rheumatoid arthritis : Predicting response to specific treatments. / O'Dell, James Robert; Nepom, Barbara S.; Haire, Claire; Gersuk, Vivian H.; Gaur, Lakshmi; Moore, Gerald Francis; Drymalski, Walter; Palmer, William; Eckhoff, P. James; Klassen, Lynell Warren; Wees, Steven; Thiele, Geoffrey Milton; Nepom, Gerald T.

In: Annals of the Rheumatic Diseases, Vol. 57, No. 4, 01.01.1998, p. 209-213.

Research output: Contribution to journalArticle

O'Dell, JR, Nepom, BS, Haire, C, Gersuk, VH, Gaur, L, Moore, GF, Drymalski, W, Palmer, W, Eckhoff, PJ, Klassen, LW, Wees, S, Thiele, GM & Nepom, GT 1998, 'HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments', Annals of the Rheumatic Diseases, vol. 57, no. 4, pp. 209-213. https://doi.org/10.1136/ard.57.4.209
O'Dell, James Robert ; Nepom, Barbara S. ; Haire, Claire ; Gersuk, Vivian H. ; Gaur, Lakshmi ; Moore, Gerald Francis ; Drymalski, Walter ; Palmer, William ; Eckhoff, P. James ; Klassen, Lynell Warren ; Wees, Steven ; Thiele, Geoffrey Milton ; Nepom, Gerald T. / HLA-DRB1 typing in rheumatoid arthritis : Predicting response to specific treatments. In: Annals of the Rheumatic Diseases. 1998 ; Vol. 57, No. 4. pp. 209-213.
@article{44664a7bdd3e47429a75ccbd2a2775e5,
title = "HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments",
abstract = "Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50{\%} response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94{\%} responders versus 32{\%}, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88{\%} responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83{\%} for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.",
author = "O'Dell, {James Robert} and Nepom, {Barbara S.} and Claire Haire and Gersuk, {Vivian H.} and Lakshmi Gaur and Moore, {Gerald Francis} and Walter Drymalski and William Palmer and Eckhoff, {P. James} and Klassen, {Lynell Warren} and Steven Wees and Thiele, {Geoffrey Milton} and Nepom, {Gerald T.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1136/ard.57.4.209",
language = "English (US)",
volume = "57",
pages = "209--213",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - HLA-DRB1 typing in rheumatoid arthritis

T2 - Predicting response to specific treatments

AU - O'Dell, James Robert

AU - Nepom, Barbara S.

AU - Haire, Claire

AU - Gersuk, Vivian H.

AU - Gaur, Lakshmi

AU - Moore, Gerald Francis

AU - Drymalski, Walter

AU - Palmer, William

AU - Eckhoff, P. James

AU - Klassen, Lynell Warren

AU - Wees, Steven

AU - Thiele, Geoffrey Milton

AU - Nepom, Gerald T.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.

AB - Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.

UR - http://www.scopus.com/inward/record.url?scp=14444268771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444268771&partnerID=8YFLogxK

U2 - 10.1136/ard.57.4.209

DO - 10.1136/ard.57.4.209

M3 - Article

VL - 57

SP - 209

EP - 213

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -